Key result
Emerging therapies targeting excitation-contraction coupling, including SERCA2a gene therapy and mechanical unloading, show potential to induce reverse remodeling and recover the failing heart.
This review highlights a conceptual framework for treating drug-refractory heart failure by combining emerging therapies that promote reverse remodeling.
Answers are grounded in this paper and cite their sources.
May support testing of excitation-contraction targets in refractory HF; leaves open efficacy in randomized trials.
Heart failure (HF) is a growing cause of morbidity and mortality globally. All clinical therapies that reduce mortality have been shown to induce reverse remodeling. In this article, we discuss a conceptual approach to the evolving treatment of HF using emerging treatment modalities for the drug-refractory patient. This approach is based on the combinatorial, integrated application of therapies shown to influence reverse remodeling in the laboratory.
No takes yet. Share an insight, caveat, or question.
Ibrahim et al. (2014) conducted a review in Heart failure. Emerging therapies (LVAD, CRT, gene therapy, cell therapy) was evaluated. Emerging therapies targeting excitation-contraction coupling, including SERCA2a gene therapy and mechanical unloading, show potential to induce reverse remodeling and recover the failing heart.
Synapse has enriched 10 related papers. Consider them for comparative context: